|
|
| (183 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | + | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| | + | *'''[[Clinical guidelines and advice]]''' |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Respiration mgmt]]''' |
| | + | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | + | |
| | + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | *
| |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32311462|t=2020. On the molecular determinants of the SARS-CoV-2 attack |pdf=|usr=}}
| |
| − | {{tp|p=32129843|t=ä. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients |pdf=|usr=}}
| |
| − | {{tp|p=32129842|t=ä. A glimpse into the origins of genetic diversity in SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32229288|t=ä. Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32271376|t=ä. Factors associated with prolonged viral RNA shedding in patients with COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | + | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
| |
| − | {{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}}
| |
| − | {{tp|p=32161940|t=ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32280952|t=ä. Good IgA bad IgG in SARS-CoV-2 infection?|pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 34: |
Zeile 39: |
| | | | |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Pathobiology]]''' |
| − | * | + | |
| | + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | *'''[[Early symptoms]]''' | | *'''[[Early symptoms]]''' |
| | + | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32358954|t=ä. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing |pdf=|usr=}}
| |
| − | {{tp|p=32361747|t=ä. COVID-19, superinfections and antimicrobial development: What can we expect?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| − | {{tp|p=32173725|t=ä. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32161968|t=ä. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias |pdf=|usr=}}
| |
| − | {{tp|p=32271373|t=ä. Predictors of refractory Coronavirus disease (COVID-19) pneumonia |pdf=|usr=}}
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32250159|t=2020. Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32178975|t=ä. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32371557|t=2020. SARS-CoV-2 and myocardial injury: Few answers, many questions |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32357210|t=ä. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32215618|t=ä. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| − | *'''[[Kidney, urology]]== | + | *'''[[The morbid survivor]]''' |
| − | *
| + | |
| − | *'''[[Pathobiology]]'''
| + | |
| | | | |
| − | *'''[[Disease Models]]''' | + | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32215622|t=ä. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | *
| |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| | | | |
| | | | |
| − | *'''[[Respiration mgmt]]'''
| |
| − | {{tp|p=32371555|t=2020. Utility of extracorporeal membrane oxygenation in COVID-19 |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| | | | |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32147731|t=ä. Diagnosis and Management of First Case of COVID-19 in Canada: Lessons applied from SARS |pdf=|usr=}}
| |
| − | {{tp|p=32227197|t=ä. A Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARS CoV2 in the United States |pdf=|usr=}}
| |
| − | {{tp|p=32211789|t=ä. The first locally acquired novel case of 2019-nCoV infection in a healthcare worker in the Paris area |pdf=|usr=}}
| |
| − | {{tp|p=32240285|t=ä. First Mildly Ill, Non-Hospitalized Case of Coronavirus Disease 2019 (COVID-19) Without Viral Transmission in the United States ? Maricopa County, Arizona, 2020 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | * | + | |
| | + | |
| | + | *'''[[Registries]]''' |
| | + | |
| | + | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| | + | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| | | | |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]''' | + | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32311512|t=ä. Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32266381|t=ä. PCR Assays Turned Positive in 25 Discharged COVID-19 Patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32302000|t=ä. The duration of viral shedding of discharged patients with severe COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | *'''[[Other routes of infection]]'''
| + | |
| − | {{tp|p=32241022|t=ä. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32297915|t=ä. Comment of the potential risks of sexual and vertical transmission of Covid-19 infection |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32315026|t=ä. Responding to the COVID-19 outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems |pdf=|usr=}}
| + | |
| − | {{tp|p=32166318|t=ä. Protecting Health Care Workers during the COVID-19 Coronavirus Outbreak ?Lessons from Taiwan s SARS response |pdf=|usr=}}
| + | |
| − | *
| + | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32371561|t=2020. Pulmonary function testing precautions in a time of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32371560|t=2020. PAP therapy increases the risk of transmission of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32252508|t=2020. Sharing Our Experience of Operating an Endoscopy Unit in the Midst of a COVID-19 Outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32371164|t=ä. RECOMMENDATIONS FOR ESSENTIAL ESOPHAGEAL PHYSIOLOGICTESTING DURING THE COVID-19 PANDEMIC |pdf=|usr=}}
| + | |
| − | {{tp|p=32304737|t=ä. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32166310|t=ä. A Novel Approach for a Novel Pathogen: using a home assessment team to evaluate patients for 2019 novel coronavirus (SARS-CoV-2) |pdf=|usr=}}
| + | |
| − | {{tp|p=32278082|t=ä. Challenges and issues about organising a hospital to respond to the COVID-19 outbreak: experience from a French reference centre |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32246142|t=ä. Care for the psychological status of frontline medical staff fighting against COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32339218|t=ä. Working schedule, sleep quality and susceptibility to COVID-19 in healthcare workers |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32371559|t=2020. Helping children cope with the COVID-19 pandemic |pdf=|usr=}}
| + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Educational aspects of the status hygienicus]]''' | | *'''[[Educational aspects of the status hygienicus]]''' |
| − | *
| + | ---- |
| | + | |
| | + | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| | + | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]''' | + | |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | + | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | + | |
| | + | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| | + | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | + | ---- |
| | + | |
| | + | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | *'''[[Current state of coviki.org]]'''
| |
| − | *[[PubMed selected papers unsorted to be listed in contents topics]]
| |
| − | *[[coviki state of development]]
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32296817|t=ä. Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials |pdf=|usr=}} | + | |
| | + | |
| | + | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | + | *'''[[from the ads]]''' |
| | + | |
| | + | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
